Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.
作者信息
Derman Benjamin A, Stefka Andrew T, Jiang Ken, McIver Amanda, Kubicki Tadeusz, Jasielec Jagoda K, Jakubowiak Andrzej J
机构信息
Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA.
Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
出版信息
Blood Cancer J. 2021 Feb 5;11(2):19. doi: 10.1038/s41408-021-00418-2.
Abstract
摘要
Zotero 插件